Acne is a prevalent chronic inflammatory disease that can cause severe psychiatric effects and physical
scarring of the skin. Historically, although systemic
antiandrogen acne medications have been effective in women, the utility of these systemic medications has been limited due to potential systemic side effects in men and pregnant women. Therefore, research has been focused on developing topical formulations of
antiandrogen therapy for
acne. Topical
clascoterone cream 1% is the first topical anti-
androgen medication approved for the treatment of
acne vulgaris in patients 12 years and older and represents a breakthrough in
acne treatment.
Clascoterone, or
cortexolone-17α
propionate, is an
androgen receptor inhibitor with highly localized activity. Thismedication is thought to compete with
dihydrotestosterone (DHT) for
androgen receptors located in pilosebaceous units, thus inhibiting the acnegenic downstream effects of DHT such as
lipid synthesis and inflammatory
cytokine production in a dose-dependent manner. Two phase III clinical trials have been conducted thus far; both trials have shown
clascoterone 1% cream applied BID to be significantly more effective than placebo cream at treating
acne vulgaris in patients ages 12 and older with moderate-to-severe
acne.
Clascoterone has also been shown to have a similar safety profile to that of placebo cream in clinical studies, without any systemic antiandrogenic effects observed in the clinical setting. Due to its novel mechanism of action and activity limited to the skin,
clascoterone presents an exciting opportunity for dermatologists to further optimize care for eligible
acne patients, either as a monotherapy or in combination with other anti-
acne medications. J Drugs Dermatol. 2023;22:56(Suppl 1):s7-14.